Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.

Clinical lung cancer - 1 Nov 2020

Tsakonas Georgios, Grozman Vitali, Ekman Simon

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Combined Modality Therapy
Share to Imidazoles
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Radiosurgery

Source

Identifiers

PMID: 32522509
DOI: 10.1016/j.cllc.2020.05.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.PMID 32522509Read ↗

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read ↗

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case SeriesSemantic proximity Read ↗

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.Semantic proximity Read ↗

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.Semantic proximity Read ↗

Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.Semantic proximity Read ↗

Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.Semantic proximity Read ↗

Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.